At the Department for Surgery of the Medical University of Vienna 544 patients were diagnosed with resectable AEG between 1992–2016 and due to missing data, a total of two hundred and sixty-five patients were included in this study.
In this collective, 216 patients (81.5%) were male, 49 (18.5%) were female. The mean age was 63.6 years, with a standard deviation of 10.9 years. The ethnicity distribution of all study patients could not be analysed due to the retrospective character of this study. 102 patients (38.5%) were neoadjuvantly treated; the other 163 patients (61.5%) received primary resection. When classified into the AEG definition, 163 patients (61.5%) were diagnosed with AEG I, 79 patients (29.8%) with AEG II, and 23 patients (8.7%) were in the AEG III group. (For a detailed characterization of the study cohort, please see Table 1.)
Table 1
Clinical characteristics between different COP-MPV groups
|
COP-MPV Score
|
|
0
|
1
|
2
|
Age (± SD)
|
62.6 (± 10.5)
|
64.2 (± 10.5)
|
64.0 (± 11.5)
|
|
n
|
%
|
n
|
%
|
n
|
%
|
Collective
|
65
|
24.5
|
139
|
52.5
|
61
|
23
|
Female
|
12
|
4.5
|
25
|
9.4
|
12
|
4.5
|
Male
|
53
|
20
|
114
|
43
|
49
|
18.5
|
G
|
|
|
|
|
|
|
0
|
3
|
1.1
|
-
|
-
|
1
|
0.3
|
1
|
2
|
0.8
|
3
|
1.1
|
1
|
0.3
|
2
|
26
|
9.8
|
67
|
25.3
|
18
|
6.8
|
3
|
34
|
12.8
|
69
|
26
|
41
|
15.5
|
AEG
|
|
|
|
|
|
|
I
|
42
|
15.8
|
87
|
32.8
|
34
|
12.8
|
II
|
17
|
6.4
|
37
|
14
|
25
|
9.4
|
III
|
6
|
2.3
|
15
|
5.7
|
2
|
0.8
|
Neoadjuvant Chemotherapy
|
|
|
|
|
|
Yes
|
25
|
9.4
|
42
|
15.8
|
35
|
13.2
|
No
|
40
|
15.5
|
97
|
36.6
|
26
|
9.8
|
Overall Survival
|
3 year OS
|
45.3%
|
5 year OS
|
26.8%
|
AEG = Adenocarcinoma of the esophagogastric junction; COP-MPV = Combination of plasma platelet count and mean platelet volume; G = histological grade; OS = Overall survival;
Applying the median values of PLT and MPV (286G/l and 10.1.fl, respectively) as a cutoff, the cohort was divided into COP-MPV subgroups. The grouping was as follows: 65 patients (24.5%) were in the COP-MPV score 0 group, 139 patients (52.5%) were scored COP-MPV-1, and 61 patients (23%) were in the score 2 group.
OS of the complete cohort was of 45.3% at three and 26.8% at 5-year follow up, respectively. The median OS for patients with COP-MPV score 0 group was 56.1 months, 32.8 months in the score 1 group and 18.8 months in the score 2 group. When reviewing the COP-MPV group individually, the highest survival rate was seen in the COP-MPV group with a score of 0 with 72.3% in 3 years and 43.1% in 5 years. Patients with a COP-MPV score of 1 had a 3-year survival of 44.6% and a 5-year survival of 28.1%. The lowest survival rates were seen in the COP-MPV group with a score of 2. These patients had a 3- and 5- year overall survival of 18% and 6.6%. The Kaplan-Meier survival analysis showed that high PLT and high MPV were associated with poor OS and DFS for all the patients (all P < 0.001) (Fig. 1a).
In univariate analyses, platelet count (p < 0.001), COP-MPV score 0 (p < 0.001), COP-MPV score 1 (p < 0.001), clinical tumor stage (p < 0.001), preoperative UICC classification (p < 0.001), Grading (p < 0.001), pT (p < 0.001), pN (p < 0.017) and Lymph-Node Ratio (p < 0.001), Mandard Response 3 (p = 0.033), neoadjuvant therapy (yes/no) (p < 0.001) were significantly associated with OS. Similar results were shown in association with DFS regarding these parameters (Table 2). Some parameters showed no significant correlation to OS, such as MPV level, sex, age nor ASA.
Table 2
Univariate analyses of overall survival and disease free survival for all patients
|
Overall Survival
|
Disease Free Survival
|
|
HR
|
95% CI
|
π
|
HR
|
95% CI
|
π
|
Sex
|
0.92
|
0.62
|
1.37
|
0.669
|
0.98
|
0.66
|
1.45
|
0.918
|
Age
|
1.00
|
0.99
|
1.02
|
0.679
|
1.00
|
0.99
|
1.01
|
0.941
|
PLT
|
3.54
|
2.58
|
4.84
|
< 0.001
|
3.07
|
2.26
|
4.18
|
< 0.001
|
MPV
|
1.02
|
0.76
|
1.37
|
0.908
|
1.09
|
0.81
|
1.47
|
0.554
|
COP-MPV (vs. 2)
|
|
|
|
|
|
|
|
|
0
|
0.26
|
0.28
|
0.40
|
< 0.001
|
0.28
|
0.18
|
0.43
|
< 0.001
|
1
|
0.39
|
0.28
|
0.57
|
< 0.001
|
0.45
|
0.32
|
0.63
|
< 0.001
|
UICC preOP (vs. III)
|
|
|
|
|
|
|
|
I
|
0.50
|
0.29
|
0.87
|
0.013
|
0.41
|
0.23
|
0.73
|
0.002
|
IIA
|
0.75
|
0.44
|
1.30
|
0.308
|
0.77
|
0.45
|
1.31
|
0.333
|
IIB
|
0.54
|
0.33
|
0.88
|
0.015
|
0.57
|
0.35
|
0.93
|
0.026
|
IVA
|
1.78
|
1.15
|
2.76
|
0.009
|
1.73
|
1.13
|
2.66
|
0.012
|
UICC postOP(vs. IIIB)
|
|
|
|
|
|
|
|
I
|
0.46
|
0.25
|
0.83
|
0.011
|
0.41
|
0.23
|
0.73
|
0.002
|
IB
|
0.14
|
0.07
|
0.30
|
< 0.001
|
0.77
|
0.45
|
1.31
|
0.333
|
IC
|
0.42
|
0.23
|
0.76
|
0.004
|
0.57
|
0.35
|
0.93
|
0.026
|
II
|
0.77
|
0.44
|
1.35
|
0.362
|
1.73
|
1.13
|
2.66
|
0.012
|
IIA
|
0.48
|
0.14
|
1.56
|
0.220
|
0.77
|
0.45
|
1.31
|
0.333
|
IIB
|
0.47
|
0.20
|
1.09
|
0.009
|
1.73
|
1.13
|
2.66
|
0.012
|
IIIA
|
0.80
|
0.50
|
1.28
|
0.308
|
0.77
|
0.45
|
1.31
|
0.333
|
IVA
|
1.55
|
0.98
|
2.45
|
0.063
|
1.73
|
1.13
|
2.66
|
0.012
|
cT (vs. 3)
|
|
|
|
|
|
|
|
|
1
|
0.56
|
0.40
|
0.78
|
< 0.001
|
0.42
|
0.28
|
0.65
|
< 0.001
|
2
|
0.47
|
0.31
|
0.71
|
< 0.001
|
0.56
|
0.40
|
0.77
|
< 0.001
|
cN (vs. I)
|
|
|
|
|
|
|
|
|
0
|
0.60
|
0.43
|
0.84
|
< 0.001
|
0.55
|
0.39
|
0.77
|
< 0.001
|
2
|
1.92
|
1.21
|
3.03
|
< 0.001
|
1.67
|
1.06
|
2.64
|
0.027
|
3
|
1.22
|
0.39
|
3.85
|
0.734
|
1.94
|
0.71
|
5.29
|
0.194
|
pT (vs. 3)
|
|
|
|
|
|
|
|
|
0
|
0.85
|
0.31
|
2.33
|
0.757
|
0.34
|
0.08
|
1.36
|
0.126
|
1
|
0.26
|
0.16
|
0.42
|
< 0.001
|
0.28
|
0.18
|
0.44
|
< 0.001
|
2
|
0.72
|
0.50
|
1.02
|
0.065
|
0.66
|
0.47
|
0.95
|
0.023
|
4
|
1.44
|
0.75
|
2.77
|
0.278
|
1.30
|
0.68
|
2.50
|
0.431
|
pN (vs. O)
|
|
|
|
|
|
|
|
|
1
|
2.41
|
1.69
|
3.42
|
< 0.001
|
2.51
|
1.76
|
3.58
|
< 0.001
|
2
|
2.76
|
1.69
|
4.51
|
< 0.001
|
2.98
|
1.84
|
4.82
|
< 0.001
|
3
|
4.42
|
2.63
|
7.45
|
< 0.001
|
4.82
|
2.92
|
7.95
|
< 0.001
|
AEG (vs. 1)
|
|
|
|
|
|
|
|
|
II
|
1.14
|
0.83
|
1.57
|
0.420
|
1.10
|
0.80
|
1.51
|
0.564
|
III
|
0.65
|
0.35
|
1.18
|
0.152
|
0.62
|
0.33
|
1.16
|
0.133
|
G (vs. 3)
|
|
|
|
|
|
|
|
|
0
|
0.91
|
0.29
|
2.86
|
0.869
|
0.62
|
0.15
|
2.51
|
0.503
|
1
|
0.48
|
0.17
|
1.31
|
0.150
|
0.52
|
0.19
|
1.40
|
0.195
|
2
|
0.46
|
0.33
|
0.63
|
< 0.001
|
0.50
|
0.36
|
0.69
|
< 0.001
|
Mandard Response* (vs. 5)
|
|
|
|
|
|
|
|
1
|
1.78
|
0.28
|
2.22
|
0.647
|
0.31
|
0.07
|
1.28
|
0.106
|
2
|
0.41
|
0.16
|
1.06
|
0.065
|
0.37
|
0.15
|
0.94
|
0.036
|
3
|
0.51
|
0.27
|
0.95
|
0.033
|
0.34
|
0.18
|
0.66
|
0.001
|
4
|
0.65
|
0.39
|
1.09
|
0.089
|
0.64
|
0.40
|
1.03
|
0.063
|
Neoadjuvant Chemotherapy
|
|
|
|
|
|
|
Yes (vs. no)
|
2.31
|
1.71
|
3.11
|
< 0.001
|
2.16
|
1.60
|
2.91
|
< 0.001
|
ASA (vs. 2)
|
|
|
|
|
|
|
|
|
1
|
1.06
|
0.72
|
1.53
|
0.775
|
1.20
|
0.83
|
1.74
|
0.325
|
3
|
1.29
|
0.81
|
2.05
|
0.287
|
1.29
|
0.82
|
2.04
|
0.271
|
4
|
0.92
|
0.22
|
3.72
|
0.905
|
0.44
|
0.06
|
3.14
|
0.411
|
p-value < 0.05; AEG = Adenocarcinoma of the esophagogastric junction; ASA = American Society of Anesthesiologists; CI = confidence interval; COP-MPV = Combination of plasma platelet count and mean platelet volume; HR = hazard ratio; G = histological grade; MPV = mean platelet volume; PLT = plasma platelet count; UICC = The Union for International Cancer Control;
* Mandard Response only applicable for neoadjuvant treated patients
Multivariate analyses for the whole cohort demonstrated that COP-MPV score 0 (p = 0.001), COP-MPV score 1 (p = 0.001), PLT (p < 0.001) were independent prognostic factors for OS (Table 5).
In the subgroup analysis of neoadjuvantly treated patients, elevated PLT, as well as a COP-MPV score of 0 and 1 (vs. 2), UICC stages, and G2 were associated with a diminished OS and DFS as well. The Cox regression analysis identified PLT (p < 0.001), COP-MPV score 0 (p < 0.001) and COP-MPV score 1 (p < 0.001) as significant prognostic factors for OS and DFS for neoadjuvantly treated patients (Table 3, 5). These findings have been visualized by Kaplan-Meier curves (Fig. 1b).
Table 3
Univariate analyses of overall survival and disease free survival for patients who received neoadjuvant treatment
|
Overall Survival
|
Disease Free Survival
|
|
HR
|
95% CI
|
π
|
HR
|
95% CI
|
π
|
Sex
|
0.59
|
0.29
|
1.18
|
0.132
|
0.57
|
0.28
|
1.13
|
0.109
|
Age
|
0.99
|
0.98
|
1.02
|
0.731
|
0.99
|
0.98
|
1.01
|
0.615
|
PLT
|
0.25
|
0.15
|
0.39
|
< 0.001
|
0.26
|
0.17
|
0.41
|
< 0.001
|
MPV
|
1.24
|
0.81
|
1.89
|
0.313
|
1.02
|
0.67
|
1.55
|
0.921
|
COP-MPV (vs. 2)
|
|
|
|
|
|
|
|
|
0
|
0.32
|
0.17
|
0.59
|
< 0.001
|
0.27
|
0.15
|
0.50
|
< 0.001
|
1
|
0.44
|
0.26
|
0.72
|
< 0.001
|
0.42
|
0.26
|
0.68
|
< 0.001
|
UICC preOP (vs. III)
|
|
|
|
|
|
|
|
|
I
|
0.87
|
0.37
|
2.02
|
0.741
|
0.65
|
0.26
|
1.62
|
0.354
|
IIA
|
1.59
|
0.68
|
3.71
|
0.283
|
1.55
|
0.66
|
3.60
|
0.311
|
IIB
|
0.91
|
0.44
|
1.87
|
0.794
|
0.97
|
0.48
|
1.97
|
0.936
|
IVA
|
1.56
|
0.86
|
2.83
|
0.141
|
1.58
|
0.89
|
2.80
|
0.120
|
UICC postOP (vs. IIIB)
|
|
|
|
|
|
|
|
I
|
0.61
|
0.32
|
1.17
|
0.137
|
0.65
|
0.29
|
1.09
|
0.089
|
II
|
1.04
|
0.56
|
1.91
|
0.910
|
0.88
|
0.47
|
1.64
|
0.690
|
IIIA
|
0.91
|
0.43
|
1.91
|
0.800
|
0.92
|
0.44
|
1.91
|
0.813
|
IVA
|
1.87
|
1.01
|
3.47
|
0.047
|
1.99
|
1.12
|
3.56
|
0.019
|
cT (vs. 3)
|
|
|
|
|
|
|
|
|
1
|
0.94
|
0.50
|
1.77
|
0.850
|
0.80
|
0.42
|
1.54
|
0.509
|
2
|
0.73
|
0.45
|
1.19
|
0.204
|
0.77
|
0.48
|
1.23
|
0.276
|
cN (vs. 1)
|
|
|
|
|
|
|
|
|
0
|
0.83
|
0.51
|
1.33
|
0.437
|
0.70
|
0.43
|
1.14
|
0.149
|
2
|
1.51
|
0.81
|
2.81
|
0.192
|
1.27
|
0.69
|
2.35
|
0.443
|
3
|
0.90
|
0.12
|
6.55
|
0.914
|
3.91
|
0.93
|
16.49
|
0.064
|
pT (vs. 3)
|
|
|
|
|
|
|
|
|
0
|
1.02
|
0.37
|
2.81
|
0.975
|
0.44
|
0.11
|
1.80
|
0.250
|
1
|
0.63
|
0.28
|
1.38
|
0.245
|
0.67
|
0.32
|
1.40
|
0.285
|
2
|
0.73
|
0.41
|
1.29
|
0.281
|
0.65
|
0.37
|
1.16
|
0.146
|
4
|
1.31
|
0.53
|
3.29
|
0.559
|
1.11
|
0.45
|
2.78
|
0.817
|
pN (vs. 0)
|
|
|
|
|
|
|
|
|
1
|
1.32
|
0.81
|
2.16
|
0.271
|
1.43
|
0.86
|
2.37
|
0.169
|
2
|
1.11
|
0.54
|
2.28
|
0.783
|
1.44
|
0.73
|
2.85
|
0.298
|
3
|
2.76
|
1.42
|
5.40
|
0.003
|
3.31
|
1.76
|
6.23
|
0.001
|
AEG (vs. 1)
|
|
|
|
|
|
|
|
|
II
|
1.17
|
0.67
|
2.03
|
0.574
|
0.97
|
0.55
|
1.70
|
0.915
|
III
|
0.77
|
0.38
|
1.59
|
0.484
|
0.69
|
0.33
|
1.45
|
0.329
|
G (vs. 3)
|
|
|
|
|
|
|
|
|
0
|
0.95
|
0.29
|
3.01
|
0.918
|
0.69
|
0.17
|
2.83
|
0.607
|
1
|
7.51
|
0.98
|
57.33
|
0.052
|
2.58
|
0.35
|
18.89
|
0.350
|
2
|
0.50
|
0.31
|
0.81
|
0.005
|
0.64
|
0.41
|
1.00
|
0.051
|
Mandard Response (vs. 5)
|
|
|
|
|
|
|
|
1
|
0.78
|
0.28
|
2.21
|
0.647
|
0.31
|
0.07
|
1.28
|
0.106
|
2
|
0.41
|
0.16
|
1.06
|
0.065
|
0.37
|
0.15
|
0.94
|
0.036
|
3
|
0.51
|
0.27
|
0.95
|
0.033
|
0.34
|
0.18
|
0.66
|
0.001
|
4
|
0.65
|
0.39
|
1.07
|
0.089
|
0.64
|
0.39
|
1.03
|
0.063
|
ASA (vs. 2)
|
|
|
|
|
|
|
|
|
1
|
1.31
|
0.82
|
2.10
|
0.265
|
1.57
|
0.99
|
2.50
|
0.058
|
3
|
1.06
|
0.52
|
2.16
|
0.881
|
1.12
|
0.57
|
2.20
|
0.751
|
4
|
2.43
|
0.59
|
10.05
|
0.221
|
1.01
|
0.14
|
7.30
|
0.995
|
p-value < 0.05; AEG = Adenocarcinoma of the esophagogastric junction; ASA = American Society of Anesthesiologists; CI = confidence interval; COP-MPV = Combination of plasma platelet count and mean platelet volume; HR = hazard ratio; G = histological grade; MPV = mean platelet volume; PLT = plasma platelet count; UICC = The Union for International Cancer Control;
In the subgroup analysis of patients undergoing primary resection of the adenocarcinoma, PLT (p < 0.001), MPV (p = 0.036), COP-MPV score 0 (p < 0.001), COP-MPV score 1 (p < 0.001), postoperative UICC classification (p < 0.001), Grading (p < 0.001), and surgery technique (one/two cavity procedure) (p = 0.022) showed in univariate analysis a reduced OS and DFS (Table 4). These findings remained independent prognostic factors for OS in multivariate analysis: PLT (p < 0.001), MPV (p = 0.039), COP-MPV score 0 (p < 0.001) and COP-MPV score 1 (p = 0.019) (Table 5). Kaplan-Meier curves emphasize these findings (Fig. 1c).
Table 4
Univariate analyses of overall survival and disease free survival for patients who underwent primary resection
|
Overall survival
|
Disease Free Survival
|
|
HR
|
95% CI
|
π
|
HR
|
95% CI
|
π
|
Sex
|
1.22
|
0.74
|
2.01
|
0.438
|
1.44
|
0.88
|
2.36
|
0.143
|
Age
|
1.01
|
0.99
|
1.04
|
0.227
|
1.01
|
0.99
|
1.03
|
0.374
|
PLT
|
3.07
|
1.99
|
4.72
|
< 0.001
|
2.42
|
1.58
|
3.69
|
< 0.001
|
MPV
|
1.57
|
1.03
|
2.39
|
0.036
|
1.65
|
1.08
|
2.52
|
0.0197
|
COP-MPV (vs. 2)
|
|
|
|
|
|
|
|
0
|
0.15
|
0.08
|
0.29
|
< 0.001
|
0.20
|
0.11
|
0.39
|
< 0.001
|
1
|
0.30
|
0.18
|
0.29
|
< 0.001
|
0.38
|
0.23
|
0.63
|
< 0.001
|
UICC preOP (vs. III)
|
|
|
|
|
|
|
|
I
|
0.36
|
0.18
|
0.73
|
0.005
|
0.30
|
0.14
|
0.64
|
0.001
|
IIA
|
0.53
|
0.26
|
1.07
|
0.077
|
0.54
|
0.27
|
1.07
|
0.075
|
IIB
|
0.35
|
0.17
|
0.70
|
0.003
|
0.38
|
0.19
|
0.76
|
0.006
|
IVA
|
0.87
|
1.19
|
4.33
|
0.012
|
2.04
|
1.07
|
3.88
|
0.030
|
AEG (vs. 1)
|
|
|
|
|
|
|
|
|
II
|
1.25
|
0.82
|
1.91
|
0.306
|
1.28
|
0.84
|
1.96
|
0.247
|
III
|
0.45
|
0.14
|
1.45
|
0.179
|
0.49
|
0.15
|
1.57
|
0.230
|
G (vs. 3)
|
|
|
|
|
|
|
|
|
1
|
0.35
|
0.11
|
1.15
|
0.084
|
0.37
|
0.11
|
0.18
|
0.093
|
2
|
0.42
|
0.27
|
0.65
|
< 0.001
|
0.41
|
0.26
|
0.63
|
< 0.001
|
ASA (vs. 2)
|
|
|
|
|
|
|
|
|
1
|
0.65
|
0.32
|
1.31
|
0.232
|
0.71
|
0.35
|
1.42
|
0.332
|
3
|
1.60
|
0.86
|
2.96
|
0.134
|
1.52
|
0.82
|
2.81
|
0.183
|
p-value < 0.05; AEG = Adenocarcinoma of the esophagogastric junction; ASA = American Society of Anesthesiologists; CI = confidence interval; COP-MPV = Combination of plasma platelet count and mean platelet volume; G = histological grade; HR = hazard ratio; MPV = mean platelet volume; PLT = plasma platelet count; UICC = The Union for International Cancer Control;
Table 5
Multivariate analyses of overall survival in all patients, neoadjuvantly treated patients and primarly resected patients
Overall Survival
|
All Patients
|
Neoadjuvantly Treated
|
Primarily Resected
|
|
HR
|
95% CI
|
π
|
HR
|
95% CI
|
π
|
HR
|
95% CI
|
π
|
PLT
|
3.72
|
2.67
|
5.18
|
< 0.001
|
0.21
|
0.12
|
0.37
|
< 0.001
|
3.18
|
1.96
|
5.17
|
< 0.001
|
Sex
|
0.96
|
0.64
|
1.46
|
0.856
|
0.52
|
0.25
|
1.09
|
0.840
|
1.66
|
0.96
|
2.88
|
0.070
|
Age
|
1.00
|
0.99
|
1.02
|
0.645
|
1.01
|
0.99
|
1.03
|
0.410
|
1.01
|
0.99
|
1.03
|
0.229
|
G (vs. 3)
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
1.53
|
0.45
|
5.22
|
0.501
|
0.57
|
0.05
|
6.19
|
0.650
|
-
|
-
|
-
|
-
|
1
|
0.43
|
0.15
|
1.21
|
0.109
|
3.44
|
0.37
|
32.23
|
0.281
|
0.48
|
0.14
|
1.71
|
0.258
|
2
|
0.62
|
0.44
|
0.89
|
0.009
|
0.85
|
0.50
|
1.45
|
0.553
|
0.53
|
0.32
|
0.88
|
0.013
|
UICC preOP (vs. III)
|
|
|
|
|
|
|
|
|
|
|
|
I
|
0.90
|
0.49
|
1.67
|
0.746
|
0.95
|
0.29
|
3.09
|
0.934
|
1.31
|
0.48
|
3.56
|
0.592
|
IIA
|
1.06
|
0.60
|
1.88
|
0.841
|
1.78
|
0.71
|
4.47
|
0.217
|
1.15
|
0.48
|
2.73
|
0.750
|
IIB
|
0.75
|
0.45
|
1.28
|
0.293
|
1.46
|
0.64
|
3.30
|
0.367
|
0.91
|
0.36
|
2.24
|
0.824
|
IVA
|
1.21
|
0.77
|
1.91
|
0.405
|
1.27
|
0.66
|
2.46
|
0.472
|
1.40
|
0.73
|
2.70
|
0.312
|
Mandard Response (vs. 5)
|
|
|
|
|
|
|
|
|
|
|
|
1
|
-
|
-
|
-
|
-
|
2.44
|
0.23
|
25.65
|
0.458
|
-
|
-
|
-
|
-
|
2
|
-
|
-
|
-
|
-
|
0.58
|
0.20
|
1.69
|
0.320
|
-
|
-
|
-
|
-
|
3
|
-
|
-
|
-
|
-
|
1.04
|
0.52
|
2.07
|
0.912
|
-
|
-
|
-
|
-
|
4
|
-
|
-
|
-
|
-
|
1.11
|
0.63
|
1.95
|
0.715
|
-
|
-
|
-
|
-
|
MPV
|
1.05
|
0.78
|
1.42
|
0.752
|
1.17
|
0.73
|
1.87
|
0.520
|
1.59
|
1.02
|
2.47
|
0.039
|
Sex
|
1.11
|
0.73
|
1.69
|
0.614
|
0.68
|
0.32
|
1.47
|
0.326
|
1.81
|
1.07
|
3.08
|
0.028
|
Age
|
1.00
|
0.99
|
1.02
|
0.486
|
0.99
|
0.97
|
1.02
|
0.612
|
1.03
|
1.00
|
1.05
|
0.019
|
G (vs. 3)
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
1.18
|
0.34
|
4.02
|
0.794
|
0.70
|
0.06
|
8.04
|
0.775
|
-
|
-
|
-
|
-
|
1
|
0.53
|
0.19
|
1.46
|
0.217
|
9.36
|
1.02
|
86.02
|
0.048
|
0.74
|
0.22
|
2.56
|
0.64
|
2
|
0.55
|
0.39
|
0.77
|
0.001
|
0.58
|
0.34
|
0.97
|
0.038
|
0.65
|
0.41
|
1.03
|
0.07
|
UICC preOP (vs. III)
|
|
|
|
|
|
|
|
|
|
|
|
I
|
0.74
|
0.41
|
1.33
|
0.313
|
1.07
|
0.35
|
3.29
|
0.912
|
1.53
|
0.56
|
4.17
|
0.403
|
IIA
|
0.95
|
0.54
|
1.69
|
0.864
|
1.51
|
0.59
|
3.88
|
0.389
|
1.78
|
0.76
|
4.21
|
0.186
|
IIB
|
0.68
|
0.40
|
1.13
|
0.136
|
0.93
|
0.40
|
2.13
|
0.860
|
1.15
|
0.45
|
2.94
|
0.773
|
IVA
|
1.40
|
0.89
|
2.18
|
0.144
|
1.35
|
0.71
|
2.54
|
0.358
|
1.77
|
0.91
|
3.44
|
0.093
|
Mandard Response (vs. 5)
|
|
|
|
|
|
|
|
|
|
|
|
1
|
-
|
-
|
-
|
-
|
1.06
|
0.10
|
10.73
|
0.963
|
-
|
-
|
-
|
-
|
2
|
-
|
-
|
-
|
-
|
0.59
|
0.20
|
1.79
|
0.353
|
-
|
-
|
-
|
-
|
3
|
-
|
-
|
-
|
-
|
0.67
|
0.33
|
1.34
|
0.252
|
-
|
-
|
-
|
-
|
4
|
-
|
-
|
-
|
-
|
0.76
|
0.44
|
1.32
|
0.338
|
-
|
-
|
-
|
-
|
COP-MPV (vs. 2)
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0.29
|
0.19
|
0.45
|
< 0.001
|
0.32
|
0.16
|
0.64
|
0.001
|
0.21
|
0.11
|
0.42
|
< 0.001
|
1
|
0.54
|
0.37
|
0.79
|
0.001
|
0.41
|
0.24
|
0.71
|
0.001
|
0.52
|
0.30
|
0.90
|
0.019
|
Sex
|
1.11
|
0.74
|
1.67
|
0.621
|
0.71
|
0.33
|
1.51
|
0.372
|
1.71
|
0.99
|
2.95
|
0.051
|
Age
|
1.00
|
0.99
|
1.02
|
0.478
|
1.00
|
0.98
|
1.02
|
0.841
|
1.02
|
1.00
|
1.04
|
0.036
|
G (vs. 3)
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
1.49
|
0.44
|
5.13
|
0.523
|
0.61
|
0.05
|
7.16
|
0.692
|
-
|
-
|
-
|
-
|
1
|
0.56
|
0.20
|
1.57
|
0.268
|
8.27
|
0.86
|
79.18
|
0.067
|
0.66
|
0.19
|
2.34
|
0.519
|
2
|
0.56
|
0.39
|
0.79
|
0.001
|
0.59
|
0.35
|
0.98
|
0.041
|
0.60
|
0.37
|
0.97
|
0.037
|
UICC preOP (vs. III)
|
|
|
|
|
|
|
|
|
|
|
|
I
|
0.80
|
0.44
|
1.45
|
0.455
|
1.11
|
0.36
|
3.44
|
0.853
|
1.55
|
0.57
|
4.23
|
0.393
|
IIA
|
0.99
|
0.56
|
1.77
|
0.992
|
1.86
|
0.72
|
4.82
|
0.204
|
1.59
|
0.68
|
3.74
|
0.285
|
IIB
|
0.76
|
0.45
|
1.28
|
0.300
|
1.31
|
0.57
|
3.03
|
0.531
|
1.00
|
0.40
|
2.53
|
0.994
|
IVA
|
1.36
|
0.87
|
2.14
|
0.183
|
1.14
|
0.59
|
2.18
|
0.702
|
1.74
|
0.90
|
3.38
|
0.101
|
Mandard Response (vs. 5)
|
|
|
|
|
|
|
|
|
|
|
|
1
|
-
|
-
|
-
|
-
|
1.15
|
0.11
|
11.58
|
0.905
|
-
|
-
|
-
|
-
|
2
|
-
|
-
|
-
|
-
|
0.53
|
0.18
|
1.52
|
0.236
|
-
|
-
|
-
|
-
|
3
|
-
|
-
|
-
|
-
|
0.63
|
0.32
|
1.23
|
0.173
|
-
|
-
|
-
|
-
|
4
|
-
|
-
|
-
|
-
|
0.82
|
0.47
|
1.43
|
0.488
|
-
|
-
|
-
|
-
|
p-value < 0.05; CI = confidence interval; COP-MPV = Combination of plasma platelet count and mean platelet volume; HR = hazard ratio; MPV = mean platelet volume; PLT = plasma platelet count;